Abstract P021 – Table 1. Proportion of participants with plasma HIV‐1 RNA <50 copies/mL at Week 48: Snapshot analysis by subgroups – ITT‐E population
| GEMINI‐1 | GEMINI‐2 | Pooled | ||||
|---|---|---|---|---|---|---|
| DTG + 3TC, n/N (%) | DTG + TDF/FTC, n/N (%) | DTG + 3TC, n/N (%) | DTG + TDF/FTC, n/N (%) | DTG + 3TC, n/N (%) | DTG + TDF/FTC, n/N (%) | |
| Overall population | 320/356 (90%) | 332/358 (93%) | 335/360 (93%) | 337/359 (94%) | 655/716 (91%) | 669/717 (93%) |
| Adjusted difference and 95% CI | −2.6 (−6.7 to 1.5) | −0.7 (−4.3 to 2.9) | −1.7 (−4.4 to 1.1) | |||
| Age (years) | ||||||
| <35 | 194/211 (92%) | 191/205 (93%) | 192/209 (92%) | 190/203 (94%) | 386/420 (92%) | 381/408 (93%) |
| 35−<50 | 100/116 (86%) | 101/107 (94%) | 111/115 (97%) | 115/122 (94%) | 211/231 (91%) | 216/229 (94%) |
| ≥50 | 26/29 (90%) | 40/46 (87%) | 32/36 (89%) | 32/34 (94%) | 58/65 (89%) | 72/80 (90%) |
| Gender | ||||||
| Female | 52/59 (88%) | 49/52 (94%) | 48/54 (89%) | 40/46 (87%) | 100/113 (88%) | 89/98 (91%) |
| Male | 268/297 (90%) | 283/306 (92%) | 287/306 (94%) | 297/313 (95%) | 555/603 (92%) | 580/619 (94%) |
| Race | ||||||
| White | 219/243 (90%) | 232/248 (94%) | 228/237 (96%) | 239/249 (96%) | 447/480 (93%) | 471/497 (95%) |
| African heritage | 39/44 (89%) | 29/36 (81%) | 44/55 (80%) | 35/40 (88%) | 83/99 (84%) | 64/76 (84%) |
| Asian | 34/37 (92%) | 41/42 (98%) | 33/34 (97%) | 27/30 (90%) | 67/71 (94%) | 68/72 (94%) |
| Other | 28/32 (88%) | 30/32 (94%) | 30/34 (88%) | 36/40 (90%) | 58/66 (88%) | 66/72 (92%) |
| Baseline HIV‐1 RNA (copies/mL) | ||||||
| ≤100,000 | 255/282 (90%) | 263/282 (93%) | 271/294 (92%) | 268/282 (95%) | 526/576 (91%) | 531/564 (94%) |
| >100,000 | 65/74 (88%) | 69/76 (91%) | 64/66 (97%) | 69/77 (90%) | 129/140 (92%) | 138/153 (90%) |
| Baseline CD4 + (cells/mm3) | ||||||
| ≤200 | 25/31 (81%) | 26/29 (90%) | 25/32 (78%) | 25/26 (96%) | 50/63 (79%) | 51/55 (93%) |
| >200 | 295/325 (91%) | 306/329 (93%) | 310/328 (95%) | 312/333 (94%) | 605/653 (93%) | 618/662 (93%) |